SCHEDULE: Avenue Capital Amends CalciMedica Loan Terms

Avenue Venture Opportunities Fund II has amended its loan agreement with CalciMedica, maintaining a 4.99% ownership blocker.

Summary

• Avenue Venture Opportunities Fund II, L.P. and related entities filed an amendment to their Schedule 13G regarding their stake in CalciMedica, Inc.
• The amendment follows a June 23, 2026, agreement to modify the existing Loan and Security Agreement dated February 28, 2025.
• The total outstanding principal amount under the amended loan is now $10,000,000.
• The lender retains the right to convert up to $3 million of the loan into common stock at $1.00 per share, subject to a 4.99% ownership blocker.
• The reporting persons beneficially own 4,641,163 shares, representing 4.99% of the company's 30,736,401 outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update regarding existing debt terms, providing no new information on operational performance.

Positives

• The amendment clarifies the terms of the $10 million debt facility, providing stability to the capital structure.
• The 4.99% ownership blocker ensures that the lender does not inadvertently trigger a change in control or exceed regulatory ownership thresholds.

Negatives

• The company remains burdened by debt obligations, with $10 million in principal currently outstanding.
• The conversion price of $1.00 per share for the $3 million portion of the loan may represent potential dilution for existing shareholders if exercised.

Risks

• The 4.99% ownership blocker limits the lender's ability to convert debt into equity, which could impact future liquidity or capital structure flexibility.
• The lender has the option to increase the ownership blocker to 19.99% with 61 days' notice, which could lead to significant future dilution.
• The company's reliance on debt financing and the potential for future equity conversion creates ongoing sensitivity to share price performance.

Future Outlook

The lender maintains the right to convert up to $3 million of the loan into equity at $1.00 per share, with the ability to increase the ownership blocker from 4.99% to 19.99% upon 61 days' notice.

Management Comments

• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects a common trend in the biotech sector where companies utilize venture debt with conversion features to extend cash runways while minimizing immediate equity dilution.

Comparison to Industry Standards

• The use of a 4.99% ownership blocker is a standard protective measure in venture debt agreements to avoid triggering 'change of control' provisions or complex regulatory filings.
• The $1.00 conversion price is consistent with typical 'at-the-money' or slightly discounted conversion features found in small-cap biotech debt facilities.

Related Party Transactions

• The reporting persons are lenders to the issuer, creating a creditor-debtor relationship.

Stakeholder Impact

• Existing shareholders face potential dilution if the $3 million debt portion is converted into common stock.

Next Steps

• Potential conversion of up to $3 million of debt into equity by the lender.
• Potential adjustment of the ownership blocker to 19.99% if the lender provides 61 days' notice.

Key Dates

Keywords

CalciMedica, Avenue Capital, Schedule 13G, Debt Financing, Equity Conversion, Biotech Finance